Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;36(5):e14774.
doi: 10.1111/nmo.14774. Epub 2024 Mar 10.

Prokinetics-safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review

Serhat Bor  1 , İsmail H Kalkan  2 , Edoardo Savarino  3 , Satish Rao  4 , Jan Tack  5 , Jay Pasricha  6 , David Cangemi  7 , Jolien Schol  8 , Tennekon Karunaratne  9 , Matteo Ghisa  10 , Nitin K Ahuja  11 , Brian Lacy  12
Affiliations
Review

Prokinetics-safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review

Serhat Bor et al. Neurogastroenterol Motil. 2024 May.

Abstract

Background: Prokinetics are a class of pharmacological drugs designed to improve gastrointestinal (GI) motility, either regionally or across the whole gut. Each drug has its merits and drawbacks, and based on current evidence as high-quality studies are limited, we have no clear recommendation on one class or other. However, there remains a large unmet need for both regionally selective and/or globally acting prokinetic drugs that work primarily intraluminally and are safe and without systemic side effects.

Purpose: Here, we describe the strengths and weaknesses of six classes of prokinetic drugs, including their pharmacokinetic properties, efficacy, safety and tolerability and potential indications.

Keywords: efficacy; gastrointestinal motility; prokinetics; safety.

PubMed Disclaimer

References

REFERENCES

    1. Quigley EM. Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. Nat Clin Pract Gastroenterol Hepatol. 2005;2(10):436‐437. doi:10.1038/ncpgasthep0292
    1. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur‐Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat Med. 1996;2(12):1382‐1385. doi:10.1038/nm1296-1382
    1. Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62(5):708‐715. doi:10.1136/gutjnl-2012-302483
    1. Soufi‐Afshar I, Moghadamnia A, Bijani A, Kazemi S, Shokri‐Shirvani J. Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. Caspian J Intern Med. 2016;7(1):19‐24.
    1. Orlando E, Finelli F, Colla M, Giotto E, Terragni P, Olivero G. Studio in doppia cecità tra neostigmina en versus placebo nell'ileo paralitico conseguente ad interventi chirurgici [A double‐blind study of neostigmine versus placebo in paralytic ileus as a result of surgical interventions]. Minerva Chir. 1994;49(5):451‐455.

Substances

LinkOut - more resources